Viatris and theravance biopharma announce positive top-line results from yupelri® (revefenacin) phase iii trial in china for the treatment of chronic obstructive pulmonary disease (copd)

Top-line results from phase iii study in china demonstrate the efficacy and safety profile of yupelri in patients with copd pittsburgh and dublin , nov. 13, 2023 /prnewswire/ -- viatris inc. (nasdaq: vtrs), a global healthcare company, and theravance biopharma, inc. (nasdaq: tbph) today announced positive results from the yupelri® (revefenacin) phase iii placebo-controlled clinical trial conducted in china assessing the efficacy and safety of yupelri, a once-daily nebulized long-acting muscarinic antagonist (lama) for the maintenance treatment of patients with copd. top-line results showed that yupelri met its primary efficacy endpoint demonstrating a statistically significant increase in trough fev1 (forced expiratory volume in one second) versus placebo.
VTRS Ratings Summary
VTRS Quant Ranking